6533b827fe1ef96bd1286dee

RESEARCH PRODUCT

Anti-hormonal maintenance treatment with or without the CDK4/6 inhibitor ribociclib after first line chemotherapy in hormone receptor positive/HER2 negative metastatic breast cancer: A phase II trial (AMICA) GBG 97

Marc ThillVolkmar MüllerV. TierbachThomas DeckerJenny FurlanettoChristoph MundhenkeMartina SchmidtS. LoiblCarsten DenkertF. SeitherK Lübbe

subject

Oncologymedicine.medical_specialtybusiness.industryHER2 negativeRibociclibHematologymedicine.diseaseMetastatic breast cancerOncologyHormone receptorInternal medicinemedicineFirst line chemotherapybusinessHormonehttps://doi.org/10.1093/annonc/mdy272.352